ASH 2024

I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

Medical Materials

Agenda

Coming soon

01:30 AM

Duration 2hrs San Diego, USA

Phase III COMMODORE 2 and 1 Trials: Characterization of Breakthrough Hemolysis Events in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated With Crovalimab or Eculizumab

Kulasekararaj A.G, Czyz J, Roncone Gastal G, Vannucchi A.M, Viigimaa l, Flynn C, Ando K, Hus M, Belén Vidriales M, Lalagianni E, Seabra P, Nur E, Scheinberg P, Röth A

Hematology | Paroxysmal Nocturnal Hemoglobinuria

10:30 PM

Duration 15mins Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4

Health Equity Impacts of Funding Emicizumab in People With Severe Hemophilia A in the US: an Aggregate Distributional Cost-Effectiveness Analysis

Thomas Majda, Janet Lee, Randall Curtis, Stacey Kowal

Hematology | Hemophilia A

01:30 AM

Duration 2hrs San Diego, USA

Phase Ill Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched From Eculizumab

Phillip Scheinberg, Diego Villa Clé, Berangere Devalet, Valentina Giai, Cristina Barrenetxea Lekue, Hsuan-Yu Lin, Zsolt Nagy, Jun-ichi Nishimura, Jens Panse, Agnieszka Piekarska, Jorg Schubert, Kazutaka Sunami, Mustafa N. Yenerel, Anita Appius, Brittany Gentile, Shino Iwase, Himika Patel, Sasha Sreckovic, Austin G. Kulasekararaj

Hematology | Paroxysmal Nocturnal Hemoglobinuria

Duration 2hrs San Diego, USA

Preclinical evaluation of NXT007 using in vitro and in vivo models of hemostasis and thrombosis

Locke M, Albiez JJ, Receveur N, Marbach S, Frey N, Girotra M, Wyssenbach M, Bektic L, David T

Hematology | Hemophilia A

Duration 2hrs San Diego, USA

Best practices to overcoming challenges in initiating venetoclax for patients with chronic lymphocytic leukemia: results from a United States community-based healthcare practitioner survey

Jacobs R, Fletcher L, Rettew A, Li SS, Eakle K, Shahkarami M, Wang R, To TM, Mathias SD, Manigault I, Burke J

Hematology - Oncology | Chronic Lymphocytic Leukemia

Duration 2hrs San Diego, USA

Incorporating Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) into Dose Review in a Phase I Clinical Trial

Mead-Harvey C, Noble BN, Yee C, Mazza GL, Langlais B, Patel S, Trask P, Rogak L, Basch E, Dueck AC, Thanarajasingam G

Hematology - Oncology | Acute Myeloid Leukemia

Duration 2hrs San Diego, USA

Reduction of Tumor Lysis Syndrome Risk after Debulking with Obinutuzumab in Patients Treated with Venetoclax-Obinutuzumab in the Randomized Phase 3 CRISTALLO Trial

Sportoletti P, Laurenti L, Ferrant E, Casado Montero LF, Mulligan SP, Harrup R, Opat S, Ibatici A, Marasca R, Boyer M, Jiang Y, Cazares O, Morschhauser F, Sharman JP

Hematology - Oncology | Chronic Lymphocytic Leukemia

Duration 2hrs San Diego, USA

Primary results of the health-related quality of life (HRQoL) and tolerability assessments from the Phase I/II NP30179 study of glofitamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)

Bachy E, Trask P, Morschhauser F, Corradini P, Wu S-J, Bartlett N, Mulvihill E, Bene Tchaleu F, Lundberg L, Carlo-Stella C

Hematology - Oncology | Diffuse large B cell lymphoma

Duration 2hrs San Diego, USA

Characterizing the US patient population receiving rituximab with gemcitabine and oxaliplatin (R-GemOx) for relapsed or refractory diffuse large B-cell lymphoma using real-world data

Budde LE, Olszewski AJ, Hu B, Shah N, Batlevi CL, Yin S, To I, Wei MC, Kallemeijn MJ, Orellana-Noia V, Musick L, Shamas N, Pal N, Shewade A, Westin J

Hematology - Oncology | Diffuse large B cell lymphoma

Duration 2hrs San Diego, USA

Glofitamab induces high response rates and durable remissions in patients with heavily pretreated relapsed/refractory mantle cell lymphoma , including those with a poor prognosis: subgroup results from a Phase I/II study

Phillips T, Trněnỳ M, Carlo-Stella C, Zaucha J, Wrobel T, Offner F, Dickinson M, Tani M, Crump M, Bartlett NL, Martinez-Lopez J, Corradini P, Mulvihill E, Bottos A, Kaufman D, Relf J, Bene Tchaleu F, Bazeos A, Lundberg L, Morschhauser F

Hematology - Oncology | Non Hodgkin Lymphoma

Duration 2hrs San Diego, USA

Bleed patterns in infants, from birth to 12 months of age, with hemophilia A treated with emicizumab: exploratory analysis of the HAVEN 7 study

Carpenter SL, Rosenfelt D, Tzeng E, Lim E, Pipe SW

Hematology | Hemophilia A

Duration 2hrs San Diego, USA

Subcutaneous mosunetuzumab leads to high rates of durable responses, low rates of cytokine release syndrome, and non-inferior exposure compared with intravenous administration in patients with relapsed/refractory follicular lymphoma: primary analysis of a pivotal Phase II study

Bartlett NL, Sehn LH, Assouline S, Giri P, Kuruvilla J, Schuster SJ, Yoon SS, Fay K, Hess G, Dreyling M, Gutierrez NC, Cybulski E, Kwan A, Penuel E, Tracy S, Kuruvilla D, Chen J, Wiebking V, Wei MC, Budde LE

Hematology - Oncology | Follicular Lymphoma

Duration 2hrs San Diego, USA

Mosunetuzumab monotherapy demonstrates encouraging activity and a manageable safety profile in patients with heavily pre-treated relapsed or refractory mantle cell lymphoma

Budde LE, Matasar M, Sehn LH, Assouline S, Kuruvilla J, Flinn IW, Yoon SS, Bosch F, Greenwald D, Gutierrez NC, Tzachanis D, Marlton P, McGuirt D, Yin S, Wei MC, Kwan A, Tracy S, Penuel E, Bartlett NL

Hematology - Oncology | Non-Hodgkin Lymphoma

Duration 2hrs San Diego, USA

A global Phase III, randomized study evaluating glofitamab plus polatuzumab vedotin + rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus Pola-R-CHP in previously untreated patients with large B-cell lymphoma

Advani R, Dickinson M, Fox CP, Kahl B, Herrera AF, Lenz G, Song Y, Tao R, Cai Q, Kim TM, Doral M, Kaufman D, Pereira LR, Berthier A, Morschhauser F

Hematology - Oncology | Diffuse large B cell lymphoma

05:30 PM

Duration 15mins Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes

Salles G, Morschhauser F, Sehn LH, Herrera AF, Friedberg JW, Trněný M, Lenz G, Sharman JP, Herbaux C, Burke JM, Matasar M, Collins GP, Song Y, Pinto A, Rai S, Izutsu K, Lee C, Chohan S, Sugidono M, Jiang Y, Batlevi CL, Yan M, Hirata J, Tilly H, Flowers CR

Hematology - Oncology | Diffuse large B cell lymphoma

08:00 PM

Duration 15mins San Diego Convention Center, Ballroom 20AB

Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

Diefenbach C, Zelenetz AD, Herbaux C, Tani M, Houot R, Bastos-Oreiro M, Tilly H, Gastinne T, Thieblemont C, Leung W, Hatzi K, Kesavan M, Boyer M, Morschhauser F

Hematology - Oncology | Diffuse large B cell lymphoma

12:45 AM

Duration 15mins Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Korfi K, Wilson S, Jiang Z, Christiansen A, Krishnan S, Jamois C, Leung W, Sam J, Blank A, Prieto I, Silva A, Knuckles P, Epp A, Hayward J, Lechner K, Dimier N, Caimi P, Falchi L, Gritti G, Morschhauser F, Hutchings M, Dickinson M, Carlo-Stella C

Hematology - Oncology | Non-Hodgkin Lymphoma

02:00 AM

Duration 2hrs San Diego, USA

Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition

Roth A, He G, Brodsky A, Chai-Adisaksopha C, Comia N.S, Kori A.N, Höglund M, J. Kelly R, Lee J, Dwilewicz Trojaczek J, Obara N, Risitano A, Gaya A, Han B

Hematology | Paroxysmal Nocturnal Hemoglobinuria

Duration 2hrs San Diego, USA

Real-World Adherence and Persistence to Emicizumab Using a National US Claims Database

Amy Shapiro, Robert Schuldt, Zhiyu Xia, Carmen Ng, Lucy Lee, Juliana Biondo, Janet Lee

Hematology | Hemophilia

Duration 2hrs San Diego, USA

A Healthcare Utilization Model Comparing Time Toxicity Between Glofitamab and Epcoritamab Treatment Regimens

Torka P, Masaquel A, Cassoli L, Fox D, Ravelo A, Major A

Hematology - Oncology | Diffuse large B cell lymphoma

Duration 2hrs San Diego, USA

Fixed-duration subcutaneous mosunetuzumab is active and has a manageable safety profile in patients with previously untreated, low-tumor burden follicular lymphoma: updated results from the Phase II MorningSun study

Burke JM, Flinn IW, Budde LE, Tun AM, Liu S, Biondo JML, Jani P, Wu M, Mun Y, Chopra VS, Grindheim JM, Farinella D, Villasboas JC

Hematology - Oncology | Follicular Lymphoma

Duration 2hrs San Diego, USA

CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia Without Del(17p) or TP53 Mutations

Sharman JP, Laurenti L, Ferrant E, Casado Montero LF, Mulligan SP, Harrup R, Opat S, Ibatici A, Marasca R, Sportoletti P, Boyer M, Jiang Y, Cazares O, Morschhauser F

Hematology - Oncology | Chronic Lymphocytic Leukemia

Duration 2hrs San Diego, USA

An economic analysis assessing the budget impact of introducing glofitamab with gemcitabine and oxaliplatin for autologous stem cell transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma to a United States health plan

Fox D, Rosettie KL, El Moustaid F, Masaquel A, Cassoli L, Flowers CR

Hematology - Oncology | Diffuse large B cell lymphoma

Duration 2hrs San Diego, USA

Evaluation of anti-tumor activity and impact on T-cell activation of glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx)

Bacac M, Sam J, Kim WS, Gregory GP, Ku M, Herter S, Klein C, Umana P, Simko S, Orellana-Noia V, Lundberg L, Bottos A

Hematology - Oncology | Diffuse large B cell lymphoma

Duration 2hrs San Diego, USA

FVIII exposure analysis from the HAVEN 7 study of emicizumab in infants with severe hemophilia A

Young G, Eakle K, Lim E, Wang M

Hematology | Hemophilia A

Duration 2hrs San Diego, USA

Venetoclax May Overcome the Prognostic Disadvantage of Short Telomeres Regarding Progression Free Survival in Previously Untreated CLL Patients with Coexisting Conditions: A Study By the German CLL Study Group (GCLLSG)

Frenzel LP, Beckmann L, Robrecht S, Zhang C, Fink AM, Al-Sawaf O, Schneider C, Chyla B, Jin HY, Jiang Y, Brümmendorf TH, Hallek M, Eichhorst BF, Fischer K, Beier F, Isfort S

Hematology - Oncology | Chronic Lymphocytic Leukemia

Duration 2hrs San Diego, USA

BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist Antibody (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Dickinson M, Hutchings M, Morschhauser F, Carlo-Stella C, Falchi L, Caimi P, Dimier N, Smith L, Whayman M, Sam J, Keelara A, Korfi K, Jamois C, Gallien J, Martin N, Martinez-Quetglas I, Hinton H, Prieto I, Michielin F, Lechner K, Gritti G

Hematology - Oncology | Non-Hodgkin Lymphoma

Duration 2hrs San Diego, USA

BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton’s Tyrosine Kinase Inhibitors in Patients with First-line Chronic Lymphocytic Leukemia

Davids MS, Burke JM, Woyach JA, Shahkarami M, Eakle K, Ko J, Chopra VS, Huang W, Farighi R, Ko RH, Sharman J, Wierda WG

Hematology - Oncology | Chronic Lymphocytic Leukemia

06:45 PM

Duration 15mins Marriott Marquis San Diego Marina, San Diego Ballroom AB

Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma

Huntington S, Masaquel A, Ma E, Zuk E, Parise H, Davis M, Fox D, El Moustaid F, Ravelo A, Cassoli L, Wu M, Frosch Z

Hematology - Oncology | Diffuse large B cell lymphoma

10:45 PM

Duration 15mins San Diego Convention Center, Ballroom 20AB

Fixed-duration glofitamab monotherapy continues to demonstrate durable responses in patients with relapsed or refractory large B-cell lymphoma: 3-year follow-up from a pivotal Phase II study

Dickinson M, Carlo-Stella C, Morschhauser F, Bachy E, Cartron G, Corradini P, Bartlett NL, Iacoboni G, Khan C, Hertzberg M, Falchi L, Brody J, Trněný M, Mulvihill E, Berthier A, Bottos A, Relf J, Bene Tchaleu F, Lundberg L, Hutchings M

Hematology - Oncology | Diffuse large B cell lymphoma

12:30 AM

Duration 15mins San Diego Convention Center, Hall B

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma: Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

Richter J, Thomas SK, Krishnan A, Laubach JP, Cohen AD, Trudel S, Costa LJ, Bahlis NJ, Forsberg PA, Kaedbey R, Fonseca R, Spencer A, Rodriguez-Otero P, Mateos M-V, Wong C, Cooper J, Tyagi T, Nakamura R, Choeurng V, Lesokhin A

Hematology - Oncology | Relapsed refractory multiple myeloma

01:00 AM

Duration 15mins Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

Glofitamab in combination with rituximab plus ifosfamide, carboplatin, and etoposide shows favorable efficacy and manageable safety in patients with relapsed or refractory diffuse large B-cell lymphoma, eligible for stem cell transplant or chimeric antigen receptor T-cell therapy: results from a Phase Ib study

Diefenbach CS, Caimi P, Saba NS, Vargas Madueno F, Hamadani M, Fayad LE, Riedell PA, Gillis-Smith A, Simko S, Orellana-Noia V, Filippou-Frye M, Kapp AV, Relf J, Lundberg L, Pinter-Brown LC

Hematology - Oncology | Diffuse large B cell lymphoma

01:15 AM

Duration 15mins Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

Glofitamab in combination with polatuzumab vedotin maintains durable responses and a manageable safety profile in patients with heavily pre-treated relapsed/refractory (R/R) large B-cell lymphoma (LBCL) including high-grade B-cell lymphoma (HGBCL): extended follow-up of a Phase Ib/II study

Hutchings M, Sureda A, Bosch F, Larsen TS, Corradini P, Avigdor A, Terol MJ, Dominguez AR, Pinto A, Skarbnik A, Cordoba R, Jørgensen J, Zinzani PL, Gurion R, Goldschmidt N, Leung W, Li D, Relf J, Tandon M, Sellam G ,Gritti G

Hematology - Oncology | Diffuse large B cell lymphoma

01:30 AM

Duration 15mins Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

A randomized Phase II study of mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL)

Chavez JC, Olszewski AJ, Bastos-Orieo M, Assouline S, Lossos IS, Diefenbach C, Ghosh N, Modi D, Sabry W, Naik S, Shah NN, Foley R, Hodson D, Makadia S, Pham S, Penuel E, Wu H, Ead WS, To I, Batlevi CL, Wei MC, Budde LE

Hematology - Oncology | Diffuse large B cell lymphoma

01:45 AM

Duration 15mins Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab is Safe and Efficacious in Patients with R/R B-NHL: Extended Follow-Up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072

Hutchings M, Dickinson M, Gritti G, Carlo-Stella C, Townsend W, Bosch F, Bartlett NL, Cartron G, Ghesquieres H, Houot R, Walter H, Offner F, Dimier N, Jamois C, Smith L, Herter S, Sahin D, Keelara A, Korfi K, Gallien J, Wasmer MH, Hinton H, Whayman M, Prieto I, Kazantzidis G, Lechner K, Morschhauser F

Hematology - Oncology | Non-Hodgkin Lymphoma

02:00 AM

Duration 2hrs San Diego, USA

Biomarker correlates and clinical activity of cevostamab in patients with triple-class refractory multiple myeloma who have received >=1 prior B-cell maturation antigen-targeted bispecific antibody: results from the Phase I/II CAMMA 2 study

Delforge M, Richter J, Cohen YC, Corradini P, Sborov D, Lesokhin A, Berdeja J, Gatt M, Paris L,Rosinol L, Quach H, Kanwar M, Catalani O, Sewpaul P,Wassner-Fritsch E, Mishra A, Trunzer K, Kumar S

Hematology - Oncology | Relapsed refractory multiple myeloma

Duration 2hrs San Diego, USA

Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched From Ravulizumab

Scheinberg P, Alzahrani H, Contento Gonzalo A, Höglund M, Kim JS, Panse J, Rose M, Schubert J, Ueda Y, Yap ES, Buri M, Compagno N, Gentile B, Sreckovic S, Kulasekararaj A

Hematology | Paroxysmal Nocturnal Hemoglobinuria

Duration 2hrs San Diego, USA

Real-World Experience With Emicizumab for Hemophilia A From the Physician Perspective Based on Survey Data

Michael Recht, Hanna Salehi, Ella Morton, Chris Blazos, Sophie Lai, Lucy Lee, Juliana Biondo, Janet Lee

Hematology - Oncology | Hemophilia A

Duration 2hrs San Diego, USA

Glofitamab with gemcitabine and oxaliplatin is cost-effective versus rituximab with gemcitabine and oxaliplatin for US patients with relapsed/refractory diffuse large B-cell lymphoma who were not candidates for autologous stem cell transplant

Fox D, El Moustaid F, Masaquel A, Rosettie KL, Celik H, Cassoli L, Flowers CR

Hematology - Oncology | Diffuse large B cell lymphoma

Duration 2hrs San Diego, USA

Primary results of patient-reported outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma treated with glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) versus rituximab plus GemOx (R-GemOx) from the Phase III STARGLO study

Gregory GP, Abramson J, Huang H-Q, Zhang Q-Y, Ku M, Yoon DH, Fox CP, Abdulhaq H, Townsend W, Ashby J, Harris A, Orellana-Noia V, Simko S, Kallemeijn M, Ta R, Relf J, Huang H, Lundberg L, Zhang H

Hematology - Oncology | Diffuse large B cell lymphoma

Duration 2hrs San Diego, USA

Mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies including those with a history of POD24: 4-year follow-up of a pivotal Phase II study

Shadman M, Bartlett NL, Matasar M, Schuster SJ, Assouline S, Sehn LH, Kuruvilla J, Giri P, Cheah CY, Dietrich S, Fay K, Ku M, Nastoupil L, Wei MC, Yin S, Ma CY, Tracy S, Kwan A, Penuel E, Budde LE

Hematology - Oncology | Follicular Lymphoma

Duration 2hrs San Diego, USA

Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

Al-Sawaf O, Locher BN, Christen F, Robrecht S, Zhang C, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Fustero C, Hablesreiter R, Seymour JF, Blombery P, Bullinger L, Chyla B, Jin HY, Jiang Y, Stilgenbauer S, Eichhorst B, Hallek M, Fischer K, Damm F

Hematology - Oncology | Chronic Lymphocytic Leukemia

I am a healthcare professional

Notice

Cookies

External site

ASH 2024